Literature DB >> 7994909

T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG).

E Brouwer1, C A Stegeman, M G Huitema, P C Limburg, C G Kallenberg.   

Abstract

T cell-mediated immunity is hypothesized to play an important role in the pathogenesis of granulomatous inflammation and vasculitis as found in patients with WG. The antigenic specificities of those T cells remain, however, unknown. Anti-neutrophil cytoplasmic antibodies (ANCA) present in patients with WG are directed to proteinase 3 (PR3) and myeloperoxidase (MPO). In the present study we investigated the proliferative capacity of peripheral blood mononuclear cells (PBMC) from patients with WG and age- and sex-matched controls in response to the WG autoantigens PR3 and MPO. Possible mitogenic effects of active PR3 and toxic effects of active MPO were excluded by using heat-inactivated PR3 and MPO. Antigen-specific stimulation induced by these autoantigens was studied by using processed PR3 and MPO in the lymphocyte stimulation test (LST). Proliferation induced by processed antigen correlated with that by heat-inactivated free antigen. The general capacity to proliferate in response to mitogens and recall antigens did not differ between patients and controls. However, patients with WG who were or had been positive for PR3-ANCA (n = 17) responded more strongly to PR3 than to MPO and showed higher responses to PR3 compared with controls (n = 13). Within the PR3-ANCA group T cell proliferation did not correlate with ANCA titre. In a small group of patients with MPO-ANCA (n = 5) no differences were observed compared with controls for MPO-specific proliferation. The data presented demonstrate that autoreactive PR3-specific T cells are present in patients with WG. Their fine specificity and possible role in the pathogenesis of WG have to be defined in further studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7994909      PMCID: PMC1534512          DOI: 10.1111/j.1365-2249.1994.tb05511.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Wegener's granulomatosis: pathology and review of the literature.

Authors:  G C GODMAN; J CHURG
Journal:  AMA Arch Pathol       Date:  1954-12

2.  Immunopathological studies of polyarteritis nodosa and Wegener's granulomatosis: a report of 43 patients with 51 renal biopsies.

Authors:  P Ronco; P Verroust; F Mignon; O Kourilsky; P Vanhille; A Meyrier; J P Mery; L Morel-Maroger
Journal:  Q J Med       Date:  1983

3.  Antimicrobial activity of myeloperoxidase.

Authors:  S J Klebanoff; A M Waltersdorph; H Rosen
Journal:  Methods Enzymol       Date:  1984       Impact factor: 1.600

4.  Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers.

Authors:  G N Gephardt; M Ahmad; R R Tubbs
Journal:  Am J Med       Date:  1983-04       Impact factor: 4.965

5.  Immunomodulation by neutrophil myeloperoxidase and hydrogen peroxide: differential susceptibility of human lymphocyte functions.

Authors:  A el-Hag; P E Lipsky; M Bennett; R A Clark
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

6.  Crescentic glomerulonephritis without immune deposits: clinicopathologic features.

Authors:  M M Stilmant; W K Bolton; B C Sturgill; G W Schmitt; W G Couser
Journal:  Kidney Int       Date:  1979-02       Impact factor: 10.612

Review 7.  Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.

Authors:  A S Fauci; B F Haynes; P Katz; S M Wolff
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

8.  Clinical and immunological follow-up of patients with severe renal disease in Wegener's granulomatosis.

Authors:  I J ten Berge; J M Wilmink; C J Meyer; J Surachno; K H ten Veen; T G Balk; P T Schellekens
Journal:  Am J Nephrol       Date:  1985       Impact factor: 3.754

9.  Purification and some properties of myeloperoxidase and eosinophil peroxidase from human blood.

Authors:  R L Olsen; C Little
Journal:  Biochem J       Date:  1983-03-01       Impact factor: 3.857

10.  In vitro stimulation of lymphocytes by neutral proteinases from human polymorphonuclear leukocyte granules.

Authors:  T L Vischer; U Bretz; M Baggiolini
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more
  26 in total

1.  Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis.

Authors:  C E Balding; A J Howie; A B Drake-Lee; C O Savage
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

Review 2.  Immunopathological aspects of systemic vasculitis.

Authors:  I M Bajema; E C Hagen; F Ferrario; E de Heer; J A Bruijn
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

Review 4.  Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  P Lamprecht
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 5.  Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

Authors:  Katayoun Rezvani; A John Barrett
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

6.  ANCA patients have T cells responsive to complementary PR-3 antigen.

Authors:  Jiajin Yang; David J Bautz; Sofia Lionaki; Susan L Hogan; Hyunsook Chin; Roland M Tisch; John L Schmitz; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

Review 7.  Peptide vaccine therapy for leukemia.

Authors:  K Rezvani
Journal:  Int J Hematol       Date:  2011-03-08       Impact factor: 2.490

8.  The role of cellular immunity in systemic vasculitis.

Authors:  P W Mathieson; D B Oliveira
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

9.  Lymphocyte counts in patients with ANCA-associated vasculitis.

Authors:  Andreas Holbro; Philipp Schuetz; Christoph Berger; Christoph Hess; Thomas Daikeler
Journal:  Rheumatol Int       Date:  2008-11-08       Impact factor: 2.631

Review 10.  Immunotherapy for myeloid leukemias: current status and future directions.

Authors:  K el-Shami; B D Smith
Journal:  Leukemia       Date:  2008-06-19       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.